Читаем без скачивания Антирак груди - Джейн Плант

310

www.ahrq.gov/news/press/pr2002/brchempr.htm

311

www.ahrq.gov/news/press/pr2002/brchempr.htm

312

http://cis.nci.nih.gov/fact/7_16.htm

313

Gottlieb, Scott, 2002. Tamoxifen may increase risk of uterine sarcoma, BMJ, 325, 7.

314

http://cis.nci.nih.gov/fact/7_16.htm

315

Mayor, Susan, 2002. Anastrozole shows promise for early breast cancer. BMJ, 324, 1539

316

www.gene.com/gene/products/information/oncology/herceptin; www.herceptin.com/herceptin/physician/pi.htm

317

http://cis.nci.nih.gov/fact/7_45.htm

318

New Scientist, 20 January, 2007.

319

Editorial, New Scientist, 31 March, 2007.

320

Josefson, Deborah, 2002. Doctors warned to be wary of new drugs. BMJ, 324, 1113.

321

Garattini, Silvio and Bertele, Vittorio, 2002. Efficacy, safety, and cost of new anticancer drugs. BMJ, 325, 269–271.

322

www.cancer.gov

323

Modified after: Chemotherapy and You: A Guide to Self-Help During Cancer Treatment. Information about what to expect during chemotherapy and what patients can do to take care of themselves during and after treatment NIH Publication #99–1136: www.cancer.gov/cancerinfo/chemorherapy-and-you

324

Smith, I. and Chue, S., 2006. Medical treatment of early breast cancer. BMJ, 332, 162–181.

325

Allison, R. and others, 2006. Photodiagnosis and photodynamic therapy, 3, 139–146.

326

Fritsch, C. and Ruzika, T., 2003. Fluorescence diagnosis and photodynamic therapy of skin diseases atlas and handbook. Vien: Springer-Verlag.

327

Абляция (лат. ablatio – отнятие) – специфическое хирургическое вмешательство; абляция подразумевает под собой выжигание или выпаривание дисфункциональной или патологически измененной ткани с использованием лазера, радиочастотного аппарата, тока или химии; также данная операция может проводиться классическим хирургическим вмешательством. – Примеч. ред.

328

Coulter; Angela, 2003. Killing the goose that laid the golden egg. BMJ, 326, 1280.

329

Coulter, Angela, 2003. Killing the goose that laid the golden egg. BMJ, 326, 1280.

330

Ernst, E., 2003. Herbal medicines put into context. BMJ, 327, 881–882.

331

Waxman, Jonathan, 2001. The Prostate Cancer Book. London: Vermillion.

332

Dyer, Owen, 2003. Aspirin could be used to prevent cancer. BMJ, 326, 565.

333

Flower, Rod, 2003. What are all the things that aspirin does? BMJ, 327, 572–573.

334

UK limits use of aspirin by under 16s. BMJ, 2002, 324, 1294.

335

Astralagus. ICON, 2002, 1 (3), 23.

336

Bartram, T., 1998. Bartram's encyclopedia of herbal medicine. Robinson publishing.

337

Campbell, T. C. and Campbell, T. M., 2006. The China Study. Benbella Books.

338

Рейки – вид комплементарной медицины, в котором используется техника так называемого исцеления путем наложения рук. – Примеч. ред.

339

Greenwald, Peter, 2002. Cancer chemoprevention. BMJ, 324, 714–718.

340

Clarke, M.F. and Becker, M.W., 2006. Stem cells: the real culprits in cancer? Scientific American, July 2006, 53–59.

341

Study reveals how growth factors affect human stem cells. www.hhmi.org/news/melton.hmtl

342

Murray, R.K., Granner, D.K., Mayes, P.A. and Rodwell, V.W., 1990. Harper's Biochemistry. Appleton and Lange Norwalk, CT, p. 653.

343

Woolf, Neville, 1998. Pathology, Basic and Systemic. W.B. Saunders Publishing Co., Chapter 28, p. 274, Figure 28.

344

www.intouchlive.com/cancergenetics/onco.htm

345

Ludwig, T., Fisher, P., Ganesan, S. and Efstratiadis, 2001. Tumorigenesis in mice carrying a truncating BRCA1 mutation. Genes and Development, Vol. 15 (10), 1188–1193.

346

Xu, X., Wagner, K.U., Larson, D., Weaver, Z., Li, C., Ried, T., Hennighausen, L., Wynshaw-Boris, A. and Deng, C.X. 1999. Conditional mutation of BRCA1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nature Genetics, Vol. 22 (1), 37–43.

347

Paull, T.T, Cortez, D., Bowers, B., Elledge, S.J. and Gellert, M., 2001. Direct DNA binding by BRCA1. Proceedings of the National Academy of Sciences of the USA , Vol. 98 (11), 6086–6091.

348

Jensen, R.A., Thompson, M.E., Jetton, T.L., Szabo, C.I., van der Meer, R., Helou, B., Tronick, S., King, M.C., Page, D.L. and Holt, J.T., 1996. BRCA1 is secreted and exhibits properties of a granin. Nature Genetics, 12, 303–308; www.mc.vanderbilt.edu/cancer/research/roster/jensen.html

349

Struewing, J.P., Abeliovich, D., Peretz, T., Avishai, N., Kaback, M.M., Collins, F.S. and Brody, L.C., 1995. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi-Jewish individuals. Nature Genetics, 11, 198–200; http://rex.nci.nih.gov/massmedia/back-grounders/ashkenazi.html

350

Roa, B.B., Boyd, A.A., Volcik, K. and Richards, C.S., 1996. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nature Genetics, 14, 185–187; Oddoux, C., Struewing, J.P., Clayton, C.M., Neuhausen, S., Vrody, L.C., Kaback, M., Haas, B., Norton, L., Borgen, P. Jhanwar, S., Golgar, D., Ostrer, H. and Offit, K., 1996. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1 %. Nature Genetics, 14, 188–190; http://rex.nci.nih.gov/massmedia/backgrounders/ashkenazi.html

351

www.mercola.com/2002/apr/27/sv40.htm

352

Hursting, S.D., Slaga,T.J., Fischer, S.M., DiGiovanni, J. and Phtans, J. M., 1999. Mechanism-based cancer prevention approaches: targets, examples, and the use of transgenic mice. Journal of the National Cancer Institute, 35, 2031–2038.

353

Cheeseman, K.H. and Slater, T.F., 1993. Free Radicals in Medicine. Churchill Livingston.

354

Cheeseman, K.H. and Slater, T.F., 1993. Free Radicals in Medicine. Churchill Livingston.

355

Stewart, H.J., 1989. Clinical experience in the use of antioestrogen tamoxifen in the treatment of breast cancer. Proceedings of the Royal Society of Edinburgh , 95B, 231–237.

356

Miller, W. R., 1997. Aromatase inhibitors and breast cancer. Cancer Treatment Reviews, 23, 113–131.

357

Dao, T.L., Sinha, D.K., Nemato, T. and Patel, J., 1982. Effects of estrogens and progesterone on cellular replication of human breast tumours. Cancer Research, 42, 359–362.

358

Conte, P.P., Fraschini, G. and Dewinko, B., 1985. Estrogen induced expansion of the growth fraction in receptor negative human breast cancer. Journal of Steroid Biochemistry, 23, 1169–1172.

359

Miller, W.R. and Langdon, S.P., 1997. Hormonal, growth factor and cytokine control of breast cancer. In: Biology of Female Cancers, pp. 43–60. Langdon, S,P., Miller, W.R. and Berchuck, A. (editors). New York: CRC Press.

360